دورية أكاديمية
Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials.
| العنوان: | Growth factor for therapeutic angiogenesis in ischemic heart disease: A meta-analysis of randomized controlled trials. |
|---|---|
| المؤلفون: | Tan L; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China., Long LZ; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China., Li HZ; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Yang WW; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China., Peng YX; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Lu JM; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Liao FF; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; Graduate School of Beijing University of Chinese Medicine, Beijing, China., Ma XC; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; National Cardiovascular Clinical Medical Research Center of TCM, Beijing, China., Qu H; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; National Cardiovascular Clinical Medical Research Center of TCM, Beijing, China., Fu CG; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.; National Cardiovascular Clinical Medical Research Center of TCM, Beijing, China., Zhang SS; Beijing Xibeiwang Town Community Health Service Center, Beijing, China. |
| المصدر: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2022 Dec 09; Vol. 10, pp. 1095623. Date of Electronic Publication: 2022 Dec 09 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2013]- |
| مستخلص: | Aim: This study was designed to systematically evaluate the effects of growth factor (GF) for therapeutic angiogenesis on ischemic heart disease (IHD) by pooling the results of randomized controlled trials (RCTs). Methods and Results: PubMed, EMBASE, and CENTRAL databases were searched from inception to October 2022. RCTs, investigating the effects of GF therapy on IHD, were included. The risk bias of included study was assessed according to Cochrane tool. Weighted mean difference (WMD), calculated with fixed effect model or random effect model, was used to evaluate the effects of GF therapy on left ventricular ejection fraction (LVEF) and Canadian Cardiovascular Society (CCS) angina class. Relative risk (RR) was used to evaluate the effects of GF therapy on all-cause mortality, major adverse cardiovascular events (MACE) and revascularization. Meta-analysis, meta-regression analysis and publication bias analysis were performed by RevMan 5.3 or Stata 15.1 software. Twenty-nine studies involving 2899 IHD patients (1,577 patients in GF group and 1,322 patients in control group) were included. Compared with the control group, GF therapy did not reduce all-cause mortality (RR: 0.82; 95% CI: 0.54-1.24; p = 0.341), MACE [(RR: 0.83; 95% CI: 0.61-1.12; p = 0.227), revascularization (RR: 1.27, 95% CI: 0.82-1.96, p = 0.290) and CCS angina class (WMD: -0.08, 95% CI: -0.36 to 0.20, p = 0.560). However, GF therapy could increase LVEF during short-term follow-up (<1 year). Conclusion: GF for therapeutic angiogenesis was beneficial for increasing LVEF during short-term follow-up (<1 year), however, the therapy was not efficacious in decreasing all-cause mortality, MACE and revascularization. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer BZ declared a shared parent affiliation with the authors H-ZL, Y-XP, J-ML, and F-FL to the handling editor at the time of review. (Copyright © 2022 Tan, Long, Li, Yang, Peng, Lu, Liao, Ma, Qu, Fu and Zhang.) |
| References: | Cardiovasc Drugs Ther. 2013 Oct;27(5):433-9. (PMID: 23784615) Circulation. 2003 Mar 18;107(10):1411-7. (PMID: 12642363) EuroIntervention. 2011 Feb;6(7):813-8. (PMID: 21252014) Circulation. 2003 Jun 3;107(21):2677-83. (PMID: 12742981) Circ J. 2018 Mar 23;82(4):1083-1091. (PMID: 29398672) Gene Ther. 2006 Nov;13(21):1503-11. (PMID: 16791287) Circ J. 2010 Jul;74(7):1415-23. (PMID: 20501957) N Engl J Med. 2020 Apr 9;382(15):1395-1407. (PMID: 32227755) J Clin Epidemiol. 2009 Oct;62(10):e1-34. (PMID: 19631507) Cardiovasc Pathol. 2016 May-Jun;25(3):214-220. (PMID: 26897485) Heart. 2012 Feb;98(4):282-90. (PMID: 22115984) Front Bioeng Biotechnol. 2022 Aug 04;10:907538. (PMID: 35992336) Eur Heart J. 2010 Nov;31(21):2593-600. (PMID: 20802250) Circulation. 2002 Apr 30;105(17):2012-8. (PMID: 11980678) Am Heart J. 2019 Sep;215:78-82. (PMID: 31288177) BMC Cardiovasc Disord. 2017 Jan 21;17(1):38. (PMID: 28109258) Mol Ther. 2009 Jun;17(6):1109-15. (PMID: 19352324) Heart. 2011 Oct;97(19):1560-5. (PMID: 21900585) Pharmacology. 2014;93(1-2):32-8. (PMID: 24434301) Eur Heart J. 2017 Sep 01;38(33):2547-2555. (PMID: 28903476) Bull Exp Biol Med. 2021 Feb;170(4):565-570. (PMID: 33730328) Curr Gene Ther. 2018;18(2):125-130. (PMID: 29618307) Eur Heart J. 2006 Aug;27(15):1785-92. (PMID: 16825290) J Am Coll Cardiol. 2005 Apr 5;45(7):982-8. (PMID: 15808751) Circ Res. 2016 Jul 8;119(2):194-6. (PMID: 27390331) Am Heart J. 2011 Mar;161(3):581-9. (PMID: 21392615) Catheter Cardiovasc Interv. 2006 Sep;68(3):372-8. (PMID: 16892433) Cardiol Ther. 2018 Dec;7(2):151-162. (PMID: 30353280) Int Heart J. 2009 May;50(3):291-9. (PMID: 19506333) Circulation. 2003 Mar 18;107(10):1359-65. (PMID: 12642354) Am Heart J. 2012 Feb;163(2):200-7.e1. (PMID: 22305837) JACC Asia. 2022 Apr 26;2(3):341-350. (PMID: 36338416) Gene Ther. 2009 May;16(5):629-34. (PMID: 19212427) J Cardiol. 2020 Sep;76(3):303-308. (PMID: 32334901) Iran J Med Sci. 2014 Mar;39(2):94-101. (PMID: 24644377) Circ Cardiovasc Interv. 2010 Oct;3(5):408-13. (PMID: 20736448) Trends Cardiovasc Med. 2018 Apr;28(3):223-228. (PMID: 29157949) Circulation. 2001 May 1;103(17):2138-43. (PMID: 11331253) Sci Rep. 2022 Nov 2;12(1):18529. (PMID: 36323953) JAMA. 2011 May 11;305(18):1863-72. (PMID: 21558517) Am J Med Sci. 2015 Feb;349(2):110-6. (PMID: 25607509) J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175) |
| فهرسة مساهمة: | Keywords: growth factor; ischemic heart disease; meta-analysis; randomized controlled study; therapeutic angiogenesis |
| تواريخ الأحداث: | Date Created: 20221226 Latest Revision: 20221227 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9780500 |
| DOI: | 10.3389/fcell.2022.1095623 |
| PMID: | 36568984 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2022.1095623 |